Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | GHSR | Q92847 | 4/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799826 | 0.90 | GHSR (0.57) | OPRD1OPRM1GHSRCCKARCCKBR | |
| SCHEMBL30799526 | 0.90 | ERAP2 (0.60) | OPRD1OPRM1GHSRMMP2MMP9 | |
| SCHEMBL31171681 | 0.90 | CASP1 (0.57) | MMP2MMP9MMP8MMP1ACE | |
| SCHEMBL30051562 | 0.89 | OPRM1 (0.60) | OPRD1OPRM1GHSRACEECE1 | |
| SCHEMBL30799750 | 0.89 | MMP9 (0.59) | OPRD1OPRM1GHSRMMP2MMP9 | |
| SCHEMBL30051669 | 0.89 | OPRM1 (0.59) | OPRD1OPRM1GHSRACEECE1 | |
| SCHEMBL30799542 | 0.89 | OPRD1 (0.55) | OPRD1OPRM1GHSRMMP2MMP9 | |
| SCHEMBL31480030 | 0.88 | ERAP2 (0.54) | MMP2MMP9MMP8MMP1CCKBR | |
| SCHEMBL30799965 | 0.87 | BACE1 (0.61) | OPRD1 | |
| SCHEMBL29559633 | 0.86 | ACE (0.62) | MMP9MMP8ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | OPRD1 4412/4885OPRM1 4382/4885GHSR 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.